Rivastigmine Transdermal System recalls
The FDA has published 1 recall involving Rivastigmine Transdermal System since 2024. The latest was reported on 3 Jan 2024. Most were for manufacturing (cgmp) deviations. Recalls usually affect specific lots, not every bottle on the market. Check the lot number on each recall page before acting.
Total recalls1since 2024
Last 12 months0reported
Class I00% of total
Ongoing0latest 3 Jan 2024
Recalls per month, last 24 months
click a bar for that monthSeverity split
Class I 0 0%Class II 1 100%Class III 0 0%
Why rivastigmine transdermal system is recalled
Companies
By year
All rivastigmine transdermal system recalls, newest first
1 total| Reported | Class | Recall | Company | Reason | Where |
|---|---|---|---|---|---|
| Drug | CLASS II | Rivastigmine Transdermal System, Delivers 4.6 mg/24 hours recalled | Cardinal Healthcare | Manufacturing (CGMP) Deviations | Nationwide |
Should you stop taking Rivastigmine Transdermal System?
Not on your own. Most recalls affect specific lots from one manufacturer, and stopping a prescription suddenly can be riskier than the defect. Check your lot number and NDC against the recall, then call the pharmacy that dispensed it for a replacement.